While JAK2 mutation is a common means to stimulate oncogenic STAT activity, perturbations in other signaling networks, such as those mediated by EGFR, IL-6/IL-6R or FLT3, can also contribute to activated STAT signaling in cancer cells [2], [43]. Here, IL6 is linked to cancer.